Novo Nordisk A/S NVO announced a definitive agreement to acquire Massachusetts-based biopharmaceutical company, Forma Therapeutics Holdings, Inc. FMTX for a total equity value of approximately $1.1 ...
Global Blood Therapeutics, Inc. GBT initiated its planned phase II/III study on its next-generation sickle hemoglobin (HbS) polymerization inhibitor, GBT02160 (GBT601) in patients with sickle cell ...
New research published today in Blood Advances indicates that many adolescent and young adult (AYA) men with sickle cell disease (SCD) are unaware of potential SCD-associated fertility issues, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback